





# IOL Chemicals and Pharmaceuticals Limited

Investor Presentation Q4 & FY26





# **Q4 & FY26 Performance**

# Q4 & FY26 Standalone Performance Highlights



Q4 FY26



**₹ 619.5 Cr**

Revenue from Operations

**▲ 17.4% YoY**



**₹ 94.3 Cr**

EBITDA

**▲ 39.8% YoY**  
EBITDA Margin **15.2%**



**₹ 53.2 Cr**

PAT

**▲ 68.2% YoY**  
PAT Margin **8.6%**

FY26



**₹ 2,319.1 Cr**

Revenue from Operations

**▲ 11.5% YoY**



**₹ 290.4 Cr**

EBITDA

**▲ 29.3% YoY**  
EBITDA Margin **12.4%**



**₹ 137.7 Cr**

PAT


**▲ 36.4% YoY**  
PAT Margin **5.9%**

# Q4 & FY26 Standalone Performance Highlights




## Pharmaceuticals

(In ₹ Cr)




## Chemicals (Net of intersegment)

(In ₹ Cr)



## Geographical Break-up



# Standalone Profit & Loss Statement – Q4 & FY26



Particulars (in INR Cr.)	Q4 FY26	Q4 FY25	Y-o-Y	Q3 FY26	Q-o-Q	FY26	FY5	Y-o-Y
<b>Revenue from Operations</b>	<b>619.5</b>	<b>527.8</b>	17.4%	<b>580.4</b>	6.7%	<b>2319.1</b>	<b>2079.2</b>	11.5%
Other Income	1.7	4.5		5.3		21.3	22.4	
<b>Total Revenue</b>	<b>621.2</b>	<b>532.3</b>	16.7%	<b>585.7</b>	6.1%	<b>2340.3</b>	<b>2101.6</b>	11.4%
Cost of Materials Consumed	401.7	347.6		356.7		1501.6	1358.3	
Purchase of Traded Goods	3.8	0.0		0.2		4.0	0.0	
Changes in Inventories of Finished Goods and Work in Progress	-33.2	-1.8		25.6		-18.5	33.5	
Employee Benefits Expense	70.3	52.4		56.9		248.3	216.6	
Other Expenses	84.3	66.7		83.7		314.6	268.6	
<b>EBITDA</b>	<b>94.3</b>	<b>67.5</b>	39.8%	<b>62.6</b>	50.8%	<b>290.4</b>	<b>224.6</b>	29.3%
<b>EBITDA %</b>	<b>15.2%</b>	<b>12.7%</b>		<b>10.7%</b>		<b>12.4%</b>	<b>10.7%</b>	
Depreciation and Amortisation Expense	20.3	18.5		20.2		80.2	71.9	
<b>EBIT</b>	<b>74.0</b>	<b>48.9</b>	51.3%	<b>42.4</b>	74.7%	<b>210.2</b>	<b>152.7</b>	37.7%
Finance Costs	3.2	4.0		3.6		14.6	14.8	
<b>Profit before exceptional items and tax</b>	<b>70.8</b>	<b>44.9</b>		<b>38.8</b>		<b>195.7</b>	<b>137.9</b>	
Exceptional items*	0.0	0.0		11.2		11.2	0.0	
<b>PBT</b>	<b>70.8</b>	<b>44.9</b>	57.8%	<b>27.6</b>	157.1%	<b>184.4</b>	<b>137.9</b>	33.8%
Total Tax Expense	17.7	13.3		7.0		46.7	36.9	
<b>Profit for the year</b>	<b>53.2</b>	<b>31.6</b>	68.2%	<b>20.6</b>	158.4%	<b>137.7</b>	<b>101.0</b>	36.4%
<b>PAT %</b>	<b>8.6%</b>	<b>5.9%</b>		<b>3.5%</b>		<b>5.9%</b>	<b>4.8%</b>	
<b>EPS</b>	<b>1.81</b>	<b>1.08</b>		<b>0.70</b>		<b>4.69</b>	<b>3.44</b>	

# Standalone Balance Sheet- FY26



Particulars (in INR Cr.)	Mar 26	Mar 25
<b>ASSETS</b>		
Non-current assets		
(i) Property, plant and equipment	1165.1	1158.0
(ii) Right to Use Asset	3.4	0.0
(iii) Capital Work in progress	93.6	20.8
(iv) Other Intangible Assets	12.8	12.3
(v) Intangible Assets under development	1.9	1.1
(vi) Financial Assets		
- Investments	17.6	17.7
- Other Financial Assets	45.1	7.9
(vii) Other Non- Current Assets	19.7	12.8
<b>Total Non-current assets</b>	<b>1359.2</b>	<b>1230.7</b>
Current assets		
(i) Inventories	371.1	360.6
(ii) Financial Assets		
- Investments	3.5	3.3
- Trade receivables	603.1	513.7
- Cash and cash equivalents	65.3	78.0
- Bank balances other than above	133.0	129.9
- Other financial Assets	7.5	5.6
(iii) Current Assets (net)	0.0	0.3
(iv) Other Current Assets	44.1	59.6
<b>Total Current Assets</b>	<b>1227.5</b>	<b>1151.1</b>
<b>TOTAL ASSETS</b>	<b>2586.7</b>	<b>2381.8</b>

Particulars (in INR Cr.)	Mar 26	Mar 25
<b>EQUITY AND LIABILITIES</b>		
EQUITY		
(i) Equity share capital	58.7	58.7
(ii) Other equity	1739.7	1628.7
<b>Total Equity</b>	<b>1798.4</b>	<b>1687.4</b>
<b>LIABILITIES</b>		
Non-current liabilities		
(i) Financial Liabilities		
-Borrowings	0.0	0.0
-Lease Liabilities	2.4	0.0
(ii) Provisions	10.9	6.7
(iii) Deferred tax Liabilities (net)	84.9	77.8
(iv) Other Non-Current Liabilities	0.0	0.0
<b>Total Non-Current Liabilities</b>	<b>98.1</b>	<b>84.5</b>
Current liabilities		
(i) Financial liabilities		
-Borrowings	132.0	117.0
-Lease Liabilities	1.0	0.0
-Trade payables	482.6	427.6
-Other financial liabilities	50.7	46.2
(ii) Other Current Liabilities	18.1	17.1
(iii) Provisions	3.5	2.0
(iv) Current Tax Liabilities	2.4	0.0
<b>Total Current Liabilities</b>	<b>690.2</b>	<b>609.9</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>2586.7</b>	<b>2381.8</b>

# Standalone Cash Flow Statement- FY26



Particulars (in INR Cr.)	Mar 26	Mar 25
<b>Cash Flow from Operating Activities</b>		
Profit before Tax	184.4	137.9
Adjustment for Non-Operating Items	85.1	79.8
<b>Operating Profit before Working Capital Changes</b>	<b>269.5</b>	<b>217.7</b>
Changes in Working Capital	-17.2	-20.7
<b>Cash Generated from Operations</b>	<b>252.3</b>	<b>197.0</b>
Less: Direct Taxes paid	-37.9	-18.3
<b>Net Cash from Operating Activities</b>	<b>214.4</b>	<b>178.7</b>
Cash Flow from Investing Activities	-198.1	-154.2
Cash Flow from Financing Activities	-29.0	46.0
<b>Net increase/ (decrease) in Cash &amp; Cash equivalent</b>	<b>-12.7</b>	<b>70.5</b>
Cash and cash equivalents at the beginning of the year	78.0	7.5
<b>Cash and cash equivalents at the end of the year</b>	<b>65.3</b>	<b>78.0</b>



# **At a Glance**

# Journey So Far



1986-91

1996-99

2000-07

2009-13

2015-16

2017-18

2019 - 20

2021-22

2023

2024

2025

2026

- **1986:** Incorporation of the Company
- **1991:** Listing on BSE, Established Acetic Acid plant.

- **2000** - Commencement of Ibuprofen Unit-1
- **2007** - Unit-01 Ibuprofen (Dedicated) Co-Generation Plant – 4MW.

- **1996** - Commencement of Ethyl Acetate Plant
- **1999** - Commencement of Acetic Anhydride Plant.

- **2009** - Commencement of IBB, MCA and Acetyl Chloride Plants
- **2010** - Listing on NSE. Co-Generation Plant – 13MW
- **2012** - Commencement of Unit-02 for Multi Product
- **2013** - Received EUGMP Certification.

- **2015** - USFDA, EIR for Ibuprofen
- **2016** - Unit-03 for new product launches.

- **2017** - Conversion of Unit-2 as Dedicated facility for Ibuprofen
- **2018** - Unit-04 Metformin (Dedicated) Unit-05 Clopidogrel & Fenofibrate.

- **2019** - Unit-06 for Pantoprazole (Dedicated)
- **2020** - Unit-07 Metformin (Dedicated).

- **2021** - Unit-08 & Unit-10 for Multi Products
- **2022** - Commenced commercial production of Paracetamol with installed capacity of 1,800 MTPA, supported by backward integration.

- Paracetamol capacity has been increased to 3,600 MTPA
- Commenced plant for Acetic Anhydride.

- Successful completion of Site Inspection by ANVISA, Brazil GMP of all 10 API's manufacturing unit and received approval in May 2024.

- Commencement of New Unit 11 (Manufacturing of Paracetamol with an installed capacity of 10,800 MTPA)
- Enhanced Capacity of Clopidogrel Bisulphate from 180 MTPA to 240 MTPA
- Incorporated IOL Pharmaxis UK Limited (wholly owned subsidiary)

- Ethyl Acetate capacity increased to 1,20,000 MTPA
- Acetic Anhydride capacity increased to 32,000 MTPA.
- Installed Triacetin Capacity of 6000 MTPA
- Enhanced Capacity of Pantoprazole to 276 MTPA.

# Business Overview





Team size of **3000+** employees

Largest producer of **Ibuprofen** and the only company worldwide being fully backward integrated

DSIR-approved R&D facility with **50+ scientists** driving innovation across APIs and specialty chemicals

Over **20** products are commercialized with **9** products in pipeline

Major producer of **Ethyl Acetate** in India with a capacity of **1,20,000 MTPA**, and **Acetic Anhydride** with a capacity of **32,000 MTPA**



Customer base across **80 countries**

Among the top global producers of **Iso Butyl Benzene (IBB)**

Existing Facility: Spanning **180+ acres**  
Expansion: Purchased **101 acres** on Chandigarh-Bathinda Highway for new site development

**Zero Discharge Effluent Treatment Plant**  
Recognized with **EcoVadis Silver Medal**-Ranks among Top 15% companies globally.

Debt to Equity Ratio **0.08**

# Segment Overview- Pharmaceuticals



Largest global producer of **Ibuprofen** with complete backward integration, having an annual capacity of **12,000 MT**

Expanding non-Ibuprofen API segment with a diversified portfolio across multiple therapeutic areas, strengthening growth beyond Ibuprofen

A fully backward-integrated and automated facility for manufacturing **paracetamol**, with an annual capacity of **10,800 MT**

14 DMFs with USFDA

21 CEPs with EDQM

The state-of-the-art facility comprises **11** dedicated units focused on efficient, high-quality production across a diversified product range

## Existing Product Portfolio

Ibuprofen

Ibuprofen Lysinate

Ibuprofen Sodium

Dex-Ibuprofen

Metformin HCL

Paracetamol

Clopidogrel

Pantoprazole Sodium

Fenofibrate

Levetiracetam

Lamotrigine

Losartan Potassium

## Application across therapeutic areas



Anti - Inflammatory



Analgesic & Antipyretic



Anti - Diabetic



Anti - Convulsant



Anti - Platelet



Anti - Epileptic



Anti- Cholesterol




Proton Pump Inhibitor



Anti- Hypertension

## Strategic Shift Towards High-Value APIs



# Segment Overview- Specialty Chemicals



Among the largest global manufacturers of Iso Butyl Benzene (IBB) worldwide


Ethyl Acetate manufacturing capacity of over 1,20,000 MTPA

Manufacturing Acetic Anhydride with capacity of 32,000 MTPA - for captive and merchant sale


Asia's first continuous dual technology plant for MCA and Acetyl Chloride using green chemistry

REACH-certified for Ethyl Acetate & Acetic Anhydride, enabling exports to EU Market


## Product Portfolio




Ethyl Acetate  
1,20,000 MTPA




Acetic Anhydride  
32,000 MTPA  
(Major Input for Paracetamol)




Iso Butyl Benzene  
12,000 MTPA  
(KSM for Ibuprofen)



Mono Chloro Acetic Acid  
7,200 MTPA  
(Input for Ibuprofen)



Acetyl Chloride  
5,200 MTPA  
(Input for Ibuprofen)



Triacetin  
6,000 MTPA

## Addressing Diverse Segments



Pharmaceuticals



Flexible Packaging



Food Processing



Paints



Ink



Textiles



Pesticides




Chemical Intermediates

# Pharmaceuticals- A Key Focus



Significant Increase in Pharma's Share of Segmental Revenue



## Expanding the non-Ibuprofen Business

	Installed Capacity	Regulatory Filings*	Therapeutic Area
<b>Metformin Hydrochloride</b>	7200 MTPA	USDMF, CEP & ANVISA GMP Approved, China DMF Active	Anti-Diabetic
<b>Fenofibrate</b>	Multiproduct Plant	USDMF, CEP & ANVISA GMP Approved, China DMF Active	Anti-Cholesterol
<b>Paracetamol (Acetaminophen)</b>	10,800 MTPA	USDMF Under Review, CEP & ANVISA GMP Approved	Analgesic & Anti-pyretic
<b>Levetiracetam</b>	Multiproduct Plant	USDMF Under Review, CEP & ANVISA GMP Approved	Anti-Epileptic
<b>Clopidogrel Bisulphate</b>	240 MTPA	USDMF Filed, CEP & ANVISA GMP Approved, China DMF Under Review	Anti-Platelet
<b>Pantoprazole Sodium</b>	276 MTPA	USDMF Filed, CEP & ANVISA GMP Approved	Proton Pump Inhibitor
<b>Lamotrigine</b>	Multiproduct Plant	USDMF Filed, CEP & ANVISA GMP Approved	Anti-Convulsant
<b>Losartan Potassium</b>	Multiproduct Plant	USDMF Filed, CEP & ANVISA GMP Approved	Anti-Hypertensive

\* Some of the listed products are also registered with other major regulatory authorities such as Korea, Taiwan and Russia

# Manufacturing Facilities



API manufactured in batch manner and intermediates & Specialty chemicals in continuous product delivery manner based on DCS technology

Dedicated and multiproduct blocks involved in manufacturing of APIs

Facility is coupled with ISO class-8 HVAC system, PSA Nitrogen & Purified water along with 185 MTPH steam generation capacity with multiple boilers

Manufacturing facilities involves – Reactions, Filtration, Centrifugation, Drying, Blending & Sieving, Micronization operation

Four stage treatment zero discharge ETP, solvent recovery plants & EHS cell as a part of the facility

Dedicated decentralized utilities from -20 to 275 deg.C temp and dedicated co-generation plant of 17MW

# Research & Development



*From Lab to Launch: 20 Products Commercialized, 9 More in Pipeline — R&D at the Heart of Our Growth Story*

**3**

**Patents**

**14**

**DMFs with USFDA**

**21**

**CEPs with EDQM**



A 120-member highly skilled team, including 50+ scientists, driving innovation across key focus areas



Working on generic molecules with latest equipment & techniques for process development



DSIR approved facility for research & development



In-house development of multi step products

# Certifications & Accreditations



				 <p>Ministry of Food and Drug Safety</p>	
<p>USFDA Approved Facility</p>	<p>EUGMP Certification</p>	<p>EDQM Certificate of Suitability</p>	<p>Halal Certified</p>	<p>DMF Registration From MFDS Korea</p>	<p>ISO 9001:2015, 14001:2015 &amp; 45001:2018</p>
					
<p>Kosher Certified</p>	<p>WHOGMP (COPP) Certified</p>	<p>Written confirmation from CDSO</p>	<p>ISO 27001 &amp; ISO 37001</p>	<p>REACH Certificate</p>	<p>GMP Certificate by Russian Federation</p>
		<p>State Food and Drug Administration</p>			
	<p>Ecovadis Silver Medal</p>	<p>State Food and Drug Administration Manufacturing License, GMP</p>	<p>Social Accountability Standard</p>	<p>CDE of NMPA, China</p>	<p>ANVISA, Brazil</p>

# Core Management Team



**Varinder Gupta** | (Managing Director)

Wide and rich experience of more than 38 years in the chemical & fertilizer industry and along with a comprehensive approach and strong Pharma API industry oversight has paved a way for innovation and excellence.



**Vikas Gupta** | (Joint Managing Director)

Academically equipped with knowledge and possesses organizational capacity. He has worked in strategic department of the Company and played a main role in guiding Chemical and Pharmaceutical business of the company. He has been vital to the functioning of the company over the last 12 years.



**Abhiraj Gupta** | (Executive Director)

Possesses requisite qualification and experience in the Company's business. He oversees the non-ibuprofen API and chemical business, R&D, regulatory, digital marketing, and strategic decisions. The non-ibuprofen API business is doing good and meeting its targets under his leadership.



**Kushal Kumar Rana** | (Director – Works)

Master's degree in Chemistry. Over 33 years in the pharmaceutical industry in companies like Morepen Laboratories, Chemiplast Industries. His expertise lies in looking after quality assurance, quality control & corporate regulatory affairs.

# Board of Directors



**Rajender Mohan Malla**  
(Chairman and Independent Director)

- With four decades of experience held top and significant decision-making positions in Banks, Financial Institutions & NBFCs
- In his most recent executive roles, he was MD & CEO of PTC India Financial Services Limited (PFS), and prior to that CMD of IDBI.



**Sharad Tyagi**  
(Independent Director)

- Over 38 years of intrapreneurship in India and international markets in diverse industries including pharmaceuticals, OTC, automotive catalysts and specialty chemicals
- Most recently until December 2020, he was the Managing Director for Boehringer Ingelheim (BI) (2009-2020), India.



**Harpal Singh**  
(Independent Director)

- Over 37 year's experience of banking and financial services
- Most recently he was General Manager of Punjab National Bank and headed entire operations of bank in State of Punjab from 2010 to 2015.




**Ms Rajni Jha**  
(Independent Director)

- Ms. Rajni Jha is a accomplished Senior Pharmaceutical Regulatory, Quality, and Compliance professional with over 32 years of experience.
- An esteemed IIT Kanpur scholar with an M.Sc. in Synthetic Organic Chemistry from Kanpur University,
- Held leadership roles at top Indian pharmaceutical giants, including Ranbaxy, Torrent, and Glenmark Pharma.

# Ensuring a Sustainable Tomorrow Through ESG Initiatives



Awarded EcoVadis Silver Medal recognizing strong ESG Performance & Global Sustainability Leadership; Ranks Among the Top 15% companies globally



- Committed towards making a difference in the lives of communities surrounding our operations through our CSR efforts and Supporting 17 UNSDGs by being member of UNGC (United Nations Global Compact)
- We strive to create sustainable and meaningful change through our philanthropic efforts, reflecting our core values and commitment to social responsibility.
- SA 8000 : 2014 Social Accountability Standard Certified Organization
- Organization has successfully completed SEDEX (SMETA) Audit on 4 Pillar approach.

- Committed to becoming carbon neutral by 2050
- 100 % State of the art Zero liquid Discharge (ZLD) Facility
- In FY25-26, Net Scope 1+ 2 Emissions intensity/ton of production has reduced by 8.8 % (excluding new plants) against FY24-25 and total Scope (1, 2 & 3 ) emissions reduced by 14.4% including new expansions
- Product Carbon Footprint Study for all Key Products and reduction plan in place
- Total 1187 KW (62.1 KW, 510 KW & 615 KW ) Capacity Solar Panels installed till date resulting in 1185 MTCO<sub>2</sub>e offset
- Approx. 61208 trees are maintained within company premises. Carbon Sink Verification completed for various plantation areas which contributes 370 MT CO<sub>2</sub>e/year in carbon sequestration.
- Our targets include a reduction in Combined Scope-01 + Scope 2 emissions by 58.8 %
- 100% reduction in Scope-02 emissions and 35% Reduction in Scope 3 by 2033 ,based on the baseline emissions of FY 2022-23.

- Defined responsibilities for Environment, Health, Safety, and Sustainability (EHS&S) have been clearly established across our sustainability leaders within the organization
- We prioritize strong and effective corporate governance to ensure the best interests of all our stakeholders
- Organization is awarded with Responsible care logo for three years by Indian Chemical Council (ICC)
- Organization is ISO 27001 Information security management system certified and ISO 37001 Anti bribery management system certified.



**100%**

Water neutral



**100%**

Zero Liquid Discharge (ZLD)



**0**

Frequency and severity rate



**80%**

Power requirement met via renewable energy



**14.4%**

Reduction in Combined Scope1+2+3 GHG Emission intensity/ton of production



**71 Score/ 89<sup>th</sup> %ile**

CDP Climate Change & Water Security Score 'B' in the 2025 Assessment Year

The background features a complex molecular structure composed of numerous spheres of varying sizes connected by thin rods. The spheres are rendered in shades of blue and green, with some appearing more prominent than others. A wide, horizontal white band is superimposed over the center of the image, providing a clear space for the text.


# Industry Overview

# API Industry- Overview




## Global API Market Size (In USD Bn)

North America holds over 38% of the API market in 2024. Asia-Pacific—led by India and China posts the fastest growth at 8.7% CAGR.



## Indian API Market Size (In USD Bn)

India is the 3<sup>rd</sup> largest API producer globally, contributing 8% to the market, with over 500 distinct APIs and 57% of WHO's prequalified APIs.



## Growth Drivers for Indian API Market

### Government Incentives

The Indian government launched a ₹6,940 crore PLI scheme in 2020, offering 6-year incentives for 41 critical APIs and KSMs.

### Robust Regulatory Compliance

India leads globally with 752 USFDA-approved pharmaceutical manufacturing facilities as of 2024, the highest number outside the U.S.

### Diversification of Global Supply Chains

COVID-19 exposed API supply risks. As a result, global pharma companies are diversifying their supply chains. With a strong manufacturing base and policy support, India is emerging as a key alternative to China for API sourcing.

### Increased R&D Investments

One of the key trends in India's pharmaceutical industry is the sharp rise in R&D investment. Companies are focusing on biosimilars, complex generics, and new chemical entities (NCEs) to drive innovation and strengthen global competitiveness.

### Quality Manufacturing

India's lower labor and production costs make it a competitive global manufacturing hub, enabling the production of high-quality drugs and vaccines at economical rates compared to developed countries.

### Rising Exports


Pharmaceutical exports from India were valued at USD 27.9 billion in FY 2023-24, showcasing a growth of 18.7% compared to the previous year. Indian pharma companies are expanding their footprint into emerging markets like Africa, Latin America, and Southeast Asia.

# Specialty Chemicals Industry- Overview




## Global Spec. Chem Market Size

(In USD Bn)




## Indian Spec. Chem Market Size

(In USD Bn)



## Region wise Spec. Chem Market Size Growth (FY25-30)



## Key Highlights

- Asia Pacific led the specialty chemicals market in 2024 with a 41.05% share, fueled by growing demand from rapidly industrializing economies like China and India
- India is the second-largest market for specialty chemicals in the Asia-Pacific region, supported by strong demand from pharmaceuticals, agrochemicals, and personal care sectors
- India enjoys a strong cost advantage in specialty chemicals, with labor and power costs significantly lower than global averages. This has positioned the country as a key growth hub in the global specialty chemicals landscape.

## India's Rising Role



China + 1 Strategy



Lower Manufacturing Cost



Favourable Government Policies



Export Growth Momentum  
(15-20% Growth)



Skilled Manpower Availability



Proximity to Feedstock & Raw Material Availability




# Historical Performance


# Historical Standalone Performance




## Revenues




## EBITDA & EBITDA %



## Cash Profit After Tax




## Segmental Revenue




■ Pharmaceuticals ■ Chemicals (net of intersegment)

## Cash Flow from Operations (Net)



## Capex Spent



\* Cash Profit After Tax = Profit Before Tax + Depreciation - Current Tax

# Summary Statement of Standalone Profit and Loss



Particulars (in INR Cr.)	FY26	FY25	FY24	FY23	FY22
<b>Revenue from Operations</b>	2319.1	2079.2	2,132.8	2,217.1	2,184.0
Other Income	21.3	22.4	30.1	25.6	32.0
<b>Total Revenue</b>	<b>2340.3</b>	<b>2101.6</b>	<b>2,162.9</b>	<b>2,242.7</b>	<b>2,216.1</b>
Cost of Materials Consumed	1501.6	1358.3	1,435.1	1,536.1	1,578.9
Purchase of Traded Goods	4.0	0.0	0.2	29.2	43.9
Changes in Inventories of Finished Goods and Work in Progress	-18.5	33.5	-38.3	-18.2	-52.3
Employee Benefits Expense	248.3	216.6	201.0	168.2	141.3
Other Expenses	314.6	268.6	303.3	275.3	215.9
<b>EBITDA</b>	<b>290.4</b>	<b>224.6</b>	<b>261.6</b>	<b>252.1</b>	<b>288.3</b>
<b>EBITDA %</b>	<b>12.4%</b>	<b>10.7%</b>	<b>12.1%</b>	<b>11.2%</b>	<b>13.0%</b>
Depreciation and Amortisation Expense	80.2	71.9	62.9	46.1	43.3
<b>EBIT</b>	<b>210.2</b>	<b>152.7</b>	<b>198.7</b>	<b>206.0</b>	<b>245.1</b>
Finance Costs	14.6	14.8	16.1	16.5	8.3
Exceptional Items	11.2	0.0	0.0	0.0	13.9
<b>PBT</b>	<b>184.4</b>	<b>137.9</b>	<b>182.6</b>	<b>189.5</b>	<b>222.8</b>
Total Tax Expense	46.7	36.9	47.2	49.5	57.2
<b>Profit for the year</b>	<b>137.7</b>	<b>101.0</b>	<b>135.4</b>	<b>140.0</b>	<b>165.7</b>
<b>PAT %</b>	<b>5.9%</b>	<b>4.8%</b>	<b>6.3%</b>	<b>6.2%</b>	<b>7.5%</b>

# Summary Statement of Standalone Balance Sheet



Particulars (in INR Cr.)	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22
<b>ASSETS</b>					
Non-current assets					
(i) Property, plant and equipment	1165.1	1,158.0	921.1	750.5	559.5
(ii) Right to Use Asset	3.4	0.0	0.0	0.1	1.0
(iii) Capital Work in progress	93.6	20.8	99.8	81.4	102.0
(iv) Other Intangible Assets	12.8	12.3	11.6	0.7	0.2
(v) Intangible Assets under development	1.9	1.1	1.0	8.2	3.2
(v) Financial Assets					
- Investments	17.6	17.7	17.7	17.7	0.1
- Other Financial Assets	45.1	7.9	48.9	233.9	205.3
(vi) Other Non- Current Assets	19.7	12.8	24.4	9.0	10.3
<b>Total Non-current assets</b>	<b>1359.2</b>	<b>1,230.7</b>	<b>1124.5</b>	<b>1101.5</b>	<b>881.6</b>
Current assets					
(i) Inventories	371.1	360.6	424.8	325.5	409.9
(ii) Financial Assets					
- Investments	3.5	3.3	2.9	2.6	2.4
- Trade receivables	603.1	513.7	471.2	505.3	469.8
- Cash and cash equivalents	65.3	78.0	7.5	1.0	1.1
- Bank balances other than above	133.0	129.9	135.1	19.9	136.8
- Other financial Assets	7.5	5.6	7.1	3.8	23.0
(iii) Current Tax Assets (net)	0.0	0.3	6.8	1.8	0.9
(iv) Other current assets	44.1	59.6	64.0	59.3	34.9
<b>Total Current Assets</b>	<b>1227.5</b>	<b>1,151.1</b>	<b>1119.5</b>	<b>919.1</b>	<b>1,078.7</b>
<b>TOTAL ASSETS</b>	<b>2586.7</b>	<b>2,381.8</b>	<b>2244.0</b>	<b>2020.6</b>	<b>1,960.3</b>

Particulars (in INR Cr.)	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22
<b>EQUITY AND LIABILITIES</b>					
EQUITY					
(i) Equity share capital	58.7	58.7	58.7	58.7	58.7
(ii) Other equity	1739.7	1,628.7	1552.6	1447.8	1331.6
<b>Total Equity</b>	<b>1798.4</b>	<b>1,687.4</b>	<b>1611.3</b>	<b>1506.6</b>	<b>1390.3</b>
LIABILITIES					
Non-current liabilities					
(i) Financial Liabilities					
-Borrowings	0.0	0.0	0.0	0.0	0.0
-Lease Liabilities	2.4	0.0	0.0	0.0	0.2
(ii) Provisions	10.9	6.7	6.7	1.7	3.0
(iii) Deferred tax Liabilities (net)	84.9	77.8	66.1	56.4	53.2
(iv) Other non-current liabilities	0.0	0.0	0.0	0.1	0.3
<b>Total Non-Current Liabilities</b>	<b>98.1</b>	<b>84.5</b>	<b>72.9</b>	<b>58.2</b>	<b>56.6</b>
Current liabilities					
(i) Financial liabilities					
-Borrowings	132.0	117.0	32.8	79.6	42.8
-Lease Liabilities	1.0	0.0	0.0	0.2	1.0
-Trade payables	482.6	427.6	469.2	314.2	409.3
-Other financial liabilities	50.7	46.2	37.6	36.0	30.0
(ii) Other Current Liabilities	18.1	17.1	16.9	17.8	23.0
(iii) Provisions	3.5	2.0	3.4	8.1	7.3
(iv) Current Tax Liabilities (net)	2.4	0.0	0.0	0.0	0.0
<b>Total Current Liabilities</b>	<b>690.2</b>	<b>609.9</b>	<b>559.8</b>	<b>455.9</b>	<b>513.4</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>2586.7</b>	<b>2,381.8</b>	<b>2244.0</b>	<b>2020.6</b>	<b>1,960.3</b>

# Summary Statement of Standalone Cashflow




Particulars (in INR Cr.)	Mar 26	Mar 25	Mar 24	Mar 23	Mar 22
<b>Cash Flow from Operating Activities</b>					
Profit before Tax	184.4	137.9	182.6	189.5	222.8
Adjustment for Non-Operating Items	85.1	79.8	59.8	44.4	33.1
<b>Operating Profit before Working Capital Changes</b>	<b>269.5</b>	<b>217.7</b>	<b>242.4</b>	<b>233.9</b>	<b>256.0</b>
Changes in Working Capital	-17.2	-20.7	90.1	-63.7	-102.3
<b>Cash Generated from Operations</b>	<b>252.3</b>	<b>197.0</b>	<b>332.5</b>	<b>170.2</b>	<b>153.6</b>
Less: Direct Taxes paid	-37.9	-18.3	-42.0	-47.1	-62.6
<b>Net Cash from Operating Activities</b>	<b>214.4</b>	<b>178.7</b>	<b>290.5</b>	<b>123.1</b>	<b>91.0</b>
Cash Flow from Investing Activities	-198.1	-154.2	-191.4	-119.2	-120.6
Cash Flow from Financing Activities	-29.0	46.0	-92.5	-4.1	-1.6
<b>Net increase/ (decrease) in Cash &amp; Cash equivalent</b>	<b>-12.7</b>	<b>70.5</b>	<b>6.6</b>	<b>-0.2</b>	<b>-31.2</b>
Cash and cash equivalents at the beginning of the year	78.0	7.5	1.0	1.1	32.3
<b>Cash and cash equivalents at the end of the year</b>	<b>65.3</b>	<b>78.0</b>	<b>7.5</b>	<b>1.0</b>	<b>1.1</b>




## Backward Integration for Margin and Supply Chain Resilience

The company adopts a strategic approach of **backward integration** for key raw materials and intermediates once products achieve significant economies of scale, ensuring enhanced control over supply, cost efficiencies, and quality



## Product Diversification Beyond Ibuprofen

The **non-Ibuprofen share** in the pharmaceuticals segment has increased from **18% to 37%** over the past six years, with a strong trajectory to further drive revenue and margin expansion over the next 2–3 years. Key products include Paracetamol, Metformin, Clopidogrel, Fenofibrate, and Pantoprazole



## Export Contribution to Rise

With **14 DMFs** and **21 CEPs**, the company is well-placed for regulated market expansion.



## Scaling Through Land Acquisition

The company has **purchased 101 acres of land** alongside the **Chandigarh-Bathinda Highway**, near its existing facility, to support future expansion. It is in the process of securing clearances for industrial use, environmental compliance, and NHA approvals

Thank You

**COMPANY :**



IOL Chemicals And Pharmaceuticals Limited

**IOL Chemicals and Pharmaceuticals Ltd.**

CIN : L24116PB1986PLC007030

Mr. Abhay Raj Singh - Sr. VP & Company Secretary

E-mail: [investor@iolcp.com](mailto:investor@iolcp.com)

[www.iolcp.com](http://www.iolcp.com)

**INVESTOR RELATIONS ADVISORS :**



**MUFG Intime India Private Limited**

A part of MUFG Corporate Markets, a division of  
MUFG Pension & Market Services

Ms. Prachi Ambre

[prachi.ambre@in.mpms.mufg.com](mailto:prachi.ambre@in.mpms.mufg.com)

Mr. Irfan Raeen

[irfan.raeen@in.mpms.mufg.com](mailto:irfan.raeen@in.mpms.mufg.com)

Meeting Request

[Link](#)



Website: <https://in.mpms.mufg.com/>